Clinical Trial Search

Primary: Number of Participant With Improvement in Foveal Thickness (Macular Fluid) as Measured by Optical Coherence Tomography (OCT) — 36 participants

Primary: Insulin Sensitivity Low Fat Diet — 6.5; 8.2; 9.8 M value (mg/kg/min

Primary: Overall Survival — 33; 39 Participants — p=0.027

Primary: Number of Participants With Serious Adverse Events (SAEs) and Severe Adverse Events — 9; 16; 5; 8 Participants — p=0.7209

Primary: Clinical Pain Intensity as Assessed by a Visual Analogue Scale (VAS) — 55.23 units on a scale

Primary: Primary Safety Endpoint — 0; 0; 0; 1 events

Primary: Time to Improvement in Coronavirus Disease 2019 (COVID-19) Clinical Status — 6.0; 10.5 Days — p=0.0367

Primary: Change From Baseline in Mineralizing Surface/Bone Surface (MS/BS) in the Cancellous Envelope at Month 3 — 5.74; 18.66 percentage of MS/BS — p=<0.0001

Primary: Number of Participants With AEs. — 143 Participants

Primary: Change in Quality of Life Post Intervention (Coaching Sessions) - Sleep — -1.06; -0.80 scores on a scale

Primary: Number of Patients With Dose-limiting Toxicities up to Week 4 After Treatment — 0; 0; 0; 0 participants

Primary: Incidence of Adverse Events — 0.756 proportion of patients

Primary: Safety- Number of Major Adverse Events at 30 Days — 2; 3; 2; 1 Events

Primary: Recruitment — 96 Participants

Primary: Accuracy of 18F-DOPA PET/CT Scans to Detect Focal Lesions in Children With Congenital Hyperinsulinism — 34; 10; 4; 52 cases